



Prostatype Genomics AB announces last day of trading in BTU and first day of trading in warrants of series TO 2

Prostatype Genomics AB's ("Prostatype Genomics" or the "Company") rights issue of units, for which the subscription period ended on 20 July 2022, has now been registered with the Swedish Companies Registration Office. The Company hereby announces that the last day of trading in paid subscribed units (Sw. BTU) will be on 10 August 2022 and stop day will be on 12 August 2022. First day of trading in warrants of series TO 2 is 16 August 2022.

In July 2022, Prostatype Genomics conducted a rights issue of units, which provided the Company with approximately SEK 22.5 million before deduction of transaction related costs of approximately SEK 3.1 million (including compensation to guarantors of approximately SEK 1.4 million). A total of 7,755,895 shares and 7,755,895 warrants of series TO 2 have been issued through the rights issue. The initial part of the rights issue has now been registered with the Swedish Companies Registration Office and the last day of trading in BTU will be on 10 August 2022 and stop day will be on 12 August 2022. The new shares and warrants of series TO 2 are estimated to be delivered to each shareholder's account on 16 August 2022.

After the registration, the total number of shares in Prostatype Genomics amounts to 22,859,497 shares and the share capital amounts to SEK 1,371,569.82. In addition, there are 7,755,895 outstanding warrants of series TO 2. The newly issued warrants of series TO 2 will be traded on Nasdaq First North Growth Market and the first day of trading will be on 16 August 2022. Warrants of series TO 2 have ISIN code SE0018220014 and will be traded under the ticker "PROGEN TO2".

Summary terms for warrants of series TO 2

Each warrant of series TO 2 entitles the holder to subscribe for one (1) new share in Prostatype Genomics during the period from 9 March 2023 until and including 30 March 2023. The exercise price will be the same price per share as the subscription price in the initial part of the rights issue, i.e. SEK 2.90. If the warrants of series TO 2 are fully exercised, the Company can be provided an additional maximum of approximately SEK 22.5 million before deduction of transaction related costs. Complete terms and conditions relating to warrants of series TO 2 are available on the Company's website (www.prostatypegenomics.com).

Advisors

In connection with the rights issue, Prostatype Genomics has engaged Sedermera Corporate Finance AB as financial advisor, Markets & Corporate Law Nordic AB as legal advisor and Nordic Issuing AB as issuing agent. Shark Communication AB has assisted the Company with advice regarding communication.

For further information about the rights issue, please contact:

Sedermera Corporate Finance AB

Phone: +46 40 615 14 10

E-mail: cf@sedermera.se

www.sedermera.se

For more information about Prostatype Genomics, please contact:

Nicklas Rosendal, press contact

Phone: +46 708-89 33 34

E-mail: nicklas.rosendal@prostatypegenomics.com

www.prostatypegenomics.com

Certified Adviser

Svensk Kapitalmarknadsgranskning AB, 011-32 30 732, ca@skmg.se

Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.